Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
The Efficacy and Safety of Liraglutide Compared to Sitagliptin, Both in Combination With Metformin in Chinese Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-12-11
- Last Posted Date
- 2017-03-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 368
- Registration Number
- NCT02008682
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Assessing the Minimal Important Difference (MID) of the Treatment Related Impact Measure-Adult Growth Hormone Deficiency (TRIM-AGHD)
Completed
- Conditions
- Growth Hormone DisorderAdult Growth Hormone Deficiency
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-12-09
- Last Posted Date
- 2017-01-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 98
- Registration Number
- NCT02005198
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Princeton, New Jersey, United States
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp in Geriatric and Younger Adult Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-12-06
- Last Posted Date
- 2018-12-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 67
- Registration Number
- NCT02003677
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Evaluating Compatibility and Safety of FIAsp and Insulin Aspart With an External Continuous Subcutaneous Insulin Infusion System in Adult Subjects With Type 1 Diabetes
Phase 3
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-12-03
- Last Posted Date
- 2017-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 37
- Registration Number
- NCT01999322
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
A Trial Investigating the Pharmacokinetic and Pharmacodynamic Properties of FIAsp When Administered as a Bolus in a Continuous Subcutaneous Infusion Regimen in Subjects With Type 1 Diabetes
Phase 1
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-11-25
- Last Posted Date
- 2016-11-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 48
- Registration Number
- NCT01992588
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Neuss, Germany
Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia
Completed
- Conditions
- Haemophilia B With InhibitorsHaemophilia A With InhibitorsHaemophilia BCongenital Bleeding DisorderHaemophilia A
- Interventions
- Other: No treatment given
- First Posted Date
- 2013-11-20
- Last Posted Date
- 2017-01-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 381
- Registration Number
- NCT01988532
- Locations
- 🇺🇸
Novo Nordisk Investigational Site, Plainsboro, New Jersey, United States
Post-marketing Surveillance (Special Use-results Surveillance) on Long-term Use With Tresiba®
Completed
- Conditions
- Diabetes Mellitus, Type 2Diabetes Mellitus, Type 1
- Interventions
- First Posted Date
- 2013-11-14
- Last Posted Date
- 2020-08-04
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 6163
- Registration Number
- NCT01984372
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Investigation on Safety, Tolerability and Pharmacokinetics of Multiple Doses of NNC0113-0987 in an Oral Formulation in Healthy Subjects
Phase 1
Completed
- Conditions
- DiabetesHealthy
- Interventions
- Drug: NNC0113-0987Drug: placebo
- First Posted Date
- 2013-11-07
- Last Posted Date
- 2014-06-30
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 100
- Registration Number
- NCT01978613
A Trial Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of a Single Dose of Long-acting Growth Hormone (Somapacitan) Compared to Daily Dosing of Norditropin® SimpleXx® in Children With Growth Hormone Deficiency
Phase 1
Completed
- Conditions
- Growth Hormone DisorderGrowth Hormone Deficiency in Children
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2020-12-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 32
- Registration Number
- NCT01973244
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Genève, Switzerland
Efficacy and Safety of Liraglutide Versus Lixisenatide as add-on to Metformin in Subjects With Type 2 Diabetes
Phase 4
Completed
- Conditions
- DiabetesDiabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2013-10-31
- Last Posted Date
- 2017-02-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 404
- Registration Number
- NCT01973231
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Taunton, United Kingdom
© Copyright 2025. All Rights Reserved by MedPath